1415303-41-1 Usage
General Description
The chemical (R)-1-(6-bromopyridin-2-yl)ethan-1-amine hydrochloride is a compound with a molecular formula C7H10BrN2. It is a salt formed from amines and hydrochloric acid, and it exists as a white solid at room temperature. (R)-1-(6-bromopyridin-2-yl)ethan-1-amine hydrochloride is used in the synthesis of pharmaceuticals and agrochemicals, specifically as an intermediate for the production of potential drug candidates. It is also used in chemical research and development as a building block for creating new molecules with potential pharmacological activity. The hydrochloride salt form of this compound aids in its solubility and stability, making it suitable for various applications in the pharmaceutical and chemical industries.
Check Digit Verification of cas no
The CAS Registry Mumber 1415303-41-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,1,5,3,0 and 3 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1415303-41:
(9*1)+(8*4)+(7*1)+(6*5)+(5*3)+(4*0)+(3*3)+(2*4)+(1*1)=111
111 % 10 = 1
So 1415303-41-1 is a valid CAS Registry Number.
1415303-41-1Relevant articles and documents
N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG
-
Page/Page column 220, (2012/12/14)
The invention provides molecular entities that bind with high affinity to PPARG (PPAR3), inhibit kinase-mediated, e.g., cdk5-mediated, phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, pre-diabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. In methods of treatment of these conditions using a compound of the invention, the compound can avoid producing side effects of significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, in the patient receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.
